Johansson et al., 1979 - Google Patents

Use of glutaraldehyde-modified timothy grass pollen extract in nasal hyposensitisation treatment of hay fever

Johansson et al., 1979

Document ID: 4756280691708848681
Author: Johansson S; Deuschl H; Zetterström O
Publication year: 1979
Publication venue: International Archives of Allergy and Immunology

External Links

Cited by

Snippet

Abstract 12 patients suffering from grass pollen hay fever were treated for 14 weeks pre-and co-seasonally by intranasal self-administration of an aqueous solution of a glutaraldehyde- treated timothy grass pollen allergen. These patients had a statistically significant decrease …

Continue reading at karger.com (other versions)

208000003385 Rhinitis, Allergic, Seasonal 0 title abstract description 11

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients

Similar Documents

Publication	Publication Date	Title
Johansson et al.	1979	Use of glutaraldehyde-modified timothy grass pollen extract in nasal hyposensitisation treatment of hay fever
Norman et al.	1978	The clinical and immunologic specificity of immunotherapy
Norman	1980	An overview of immunotherapy: implications for the future
Andri et al.	1993	Local nasal immunotherapy for Dermatophagoides-induced rhinitis: efficacy of a powder extract
Nelson et al.	1993	A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract
Nickelsen et al.	1981	Local intranasal immunotherapy for ragweed allergic rhinitis I. Clinical response
TAYLOR et al.	1972	Local nasal desensitization in allergic rhinitis
Cooper et al.	1984	A controlled trial of oral hyposensitization in pollen asthma and rhinitis in children
D'AMATO et al.	1995	A double‐blind, placebo‐controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen
Ortolani et al.	1994	A double‐blind, placebo‐controlled study of immunotherapy with an alginate‐conjugated extract of Parietaria judaica in patients with Parietaria hay fever
Litwin et al.	1991	Regulation of the human immune response to ragweed pollen by immunotherapy. A controlled trial comparing the effect of immunosuppressive peptic fragments of short ragweed with standard treatment
Holt et al.	1982	Tolerance induction via antigen inhalation: isotype specificity, stability, and involvement of suppressor T cells
JP2004529180A (en)	2004-09-24	Compositions for use in treating IgE-related disorders
Kägi et al.	2002	Different methods of local allergen-specific immunotherapy.
Andri et al.	1995	Local nasal immunotherapy for birch allergic rhinitis with extract in powder form
NO144056B (en)	1981-03-09	DEVICE FOR ARTIFICIAL WATERING OF FLOWER BEDS, GARDENS ETC.
Schumacher et al.	1982	Intranasal Immunotherapy with Polymerized Grass Pollen Allergens: A Pilot Study
Lichtenstein et al.	1968	Antibody response following immunotherapy in ragweed hay fever: Allpyral vs. whole ragweed extract
ØSterballe	1982	Nasal and skin sensitivity during immunotherapy with two major allergens 19, 25 and partially purified extract of timothy grass pollen
Mistrello et al.	1991	Detection of IgE‐binding activity in serum after intranasal treatment of normal rabbits with P. judaica extract
Cockcroft et al.	1977	Allergen injection therapy with glutaraldehyde-modified—ragweed pollen-tyrosine adsorbate: A double-blind trial
Bernstein et al.	1979	Immunoregulatory Function of Specific IgG: II. Clinical Evaluation of Combined Active and Passive Immunotherapy
Möller et al.	1994	Nedocromil sodium 2% eye drops for twice‐daily treatment of seasonal allergic conjunctivitis: a Swedish multicentre placebo‐controlled study in children allergic to birch pollen
Mathews et al.	1981	Controlled studies of intranasal immunotherapy for ragweed pollenosis
Leiferman et al.	1975	The effect of cromolyn sodium powder as a treatment for ragweed pollinosis